Talphera Inc reports results for the quarter ended June 30 - Earnings Summary
Talphera Inc reports results for the quarter ended June 30 - Earnings Summary
Talphera Inc TLPH.OQ reported a quarterly adjusted loss of 6 cents per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -10 cents. The mean expectation of three analysts for the quarter was for a loss of 7 cents per share. Wall Street expected results to range from -7 cents to -6 cents per share.
Reported revenue was zero; analysts expected zero.
Talphera Inc's reported EPS for the quarter was a loss of 6 cents.
The company reported a quarterly loss of $4.31 million.
Talphera Inc shares had risen by 42.7% this quarter and gained 28.9% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 4.8% in the last three months.
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"
This summary was machine generated from LSEG data August 12 at 09:01 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Jun. 30 2026 | -0.07 | -0.06 | Beat |
Mar. 31 2026 | -0.07 | -0.04 | Beat |
Dec. 31 2025 | -0.08 | -0.06 | Beat |
Sep. 30 2025 | -0.14 | -0.11 | Beat |
Recent news on Talphera
See all newsTalphera Inc reports results for the quarter ended June 30 - Earnings Summary
Talphera Inc expected to post a loss of 7 cents a share - Earnings Preview
Talphera Q1 net loss narrows as costs rise on higher development spending
Talphera Q4 net loss widens as operating expenses rise
Brief: Talphera Announces 50% Enrollment Milestone In Ongoing Nephro-Crrt Registrational Trial